ClinicalThought
View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of molecular testing and classification to guide the use of immunotherapy for the treatment of patients with endometrial cancer.
Presenters:
Ana Oaknin, MD, PhD
Head of Gynecologic Tumors Unit
Medical Oncology Department
Vall d´Hebron University Hospital
Barcelona, Spain
Mansoor Raza Mirza, MD
Chief Oncologist
Department of Oncology,
Rigshopitalet – Copenhagen University Hospital
Copenhagen, Denmark
Comentario clínico en español sobre la reclasificación molecular de los cánceres de endometrio y ensayos clave de inmunoterapia en curso, de Clinical Care Options (CCO)
Domenica Lorusso, MD, PhD
Released: May 10, 2021
Jubilee Brown, MD, and Ursula Matulonis, MD, discuss current challenges in the management of endometrial and ovarian cancer, from Clinical Care Options (CCO)
Jubilee Brown, MD
Ursula Matulonis, MD
Released: May 3, 2021
Download slides from Clinical Care Options (CCO) in which experts provide multidisciplinary insights on the use of checkpoint inhibitors for HCC
Lipika Goyal, MD
Amit G. Singal, MD, MS
Released: April 30, 2021
From Clinical Care Options (CCO), webcast and downloadable slides on the use of PARP inhibitors to treat ovarian cancer, with Italian subtitles
Alexandra Leary, MD, PhD
Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci
Frederik Marmé, MD, PhD
Released: April 29, 2021
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.